English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The Trial of Preventing Hypertension (TROPHY) Study is designed to establish whether treating high normal blood pressure with a low-dose angiotensin receptor blocker, candesartan cilexetil, for 2 years reduces the rate of progression to hypertension compared with placebo treatment over a 4-year observation period. We are presenting the baseline cardiovascular risk factor profile of the 809 subjects randomized in the TROPHY Study. The risk factors in this analysis were as follows: cholesterol &gt;or=200 mg/dl; LDL-cholesterol &gt;or=160 mg/dL; HDL-cholesterol &lt;or=40 mg/dL (for men), &lt;or=50 mg/dL (for women); triglycerides &gt;or=150 mg/dL; body mass index &gt;or=25 kg/m2 (overweight and obese), fasting insulin &gt;or=20 mU/mL; heart rate &gt;or=80 beats/min; hematocrit &gt;or=43.5 % (men) and &gt;or=41.2% (women).

Is Low-Risk Hypertension Fact or Fiction?Cardiovascular Risk Profile in the TROPHY Study